FORMULATION AND IN-VITRO EVALUATION OF CONTROLLED POROSITY OSMOTIC PUMP TABLETS OF TELMISARTAN FOR SUSTAINED RELEASE DRUG DELIVERY

The purpose of the present research was for the development and assessment of controlled porosity osmotic pump (CPOP) tablets for the long-term oral administration of the poorly soluble hypertension medication telmisartan. The objective was to use an osmotic formulation technique that would improve the drug dissolution and bioavailability. FT-IR was used in order to confirm drug-excipient compatibility and validate analytical procedures. SLS was used as a pore-forming agent in a cellulose acetate membrane that was applied to tablets that were made by direct compression. A number of formulations were tested after it had been determined that all quality criteria satisfied requirements. Following zero-order kinetics, the lead formulation, F9C2 with a 5% coating, showed a steady, nearly full drug release (97.93% over 8 hours). Stability studies and SEM imaging confirmed the formulation's prolonged stability and consistent pore distribution, making it an appropriate approach for enhancing Telmisartan's therapeutic efficacy.